FDA Approves Pfizer's RSV Vaccine for Seniors After Success in Late-Stage Trials

Pfizer's respiratory syncytial virus (RSV) vaccine for older adults has been approved by the FDA.
Pfizer's vaccine was found to be 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% against severe illness defined by three or more symptoms.
RSV is a highly contagious virus that can be dangerous for seniors.
Pfizer vaccine was 66.7% effective at preventing moderated lower respiratory tract illness with two or more symptoms and 85.7% effective at preventing illness with three or more symptoms in people 60 and older.
The vaccine is expected to be available before the start of next RSV season.